Just now! The second round of national drug collection results outflow

Finishing: looking forward Just now! The results of the second round of national drug centralized purchase and pre selection outflow On the afternoon of January 17, Shanghai Sunshine pharmaceutical purchasing network released the results of the second round of national drug pre selection It is reported that the results of the selection were officially released three days later, and patients from all over the country could use this batch of selected drugs in April According to rough statistics, in the second round of national drug collection, the decline rate of selected drug companies was basically between 60% and 80%, the highest decline rate was given by Hunan Jiudian Pharmaceutical Co., Ltd., and the drop rate of levocetirizine oral regular release dosage form was 93% According to Huaxi pharmaceutical, Hengrui Pharmaceutical Co., Ltd won the bidding for all varieties: among them, the bidding price of albumin paclitaxel is 780 yuan per piece, with a price reduction rate of 75%; abitrone is 31.9 yuan per piece, with a price reduction rate of 70%; tegio is 5.66 yuan per piece, with a price reduction rate of 74%; it basically meets the expectation, with a purchase amount of about 25 million yuan, 25 million yuan and 83 million yuan respectively 1.8 times of the minimum price limit rule was triggered for the first time, and 2 of acarbose 4: the minimum price limit of 1.8 times of the new centralized purchase rule was triggered for the first time The prices of acarbose Bayer, green leaf, Beijing Fuyuan, China and the United States and East China were respectively 0.20 yuan, 0.36 yuan, 0.49 yuan, and 0.53 yuan, respectively The comprehensive n-1 and 1.8 times of the limit price, Beijing Fuyuan higher than Bayer 1.8 times of the limit price, failed to win the bid Bayer, with a 78% drop, shot the whole game For glimepiride, the price limit of 1mg is 0.1765 yuan, and the price limit of 2mg is 0.3 yuan; for Chongqing kangkeri, the price limit is 0.0530 yuan / tablet, a 70% decrease; different from Bayer's low-cost bid for acarbose, Sanofi's 2mg specification is waived Albumin paclitaxel, price limit 2400 yuan: Hengrui quoted 780 yuan, a decrease of 67.5%; stone medicine quoted 747 yuan, a decrease of 68.9%, winning the bid at the lowest price; Qilu quoted 1828 yuan, a decrease of 44.3%, less than 50%, basically giving up the variety; the original research agency Baiji quoted 1150 yuan / bottle, a decrease of 52% It is worth noting that albumin paclitaxel is the most special product in this drug collection It has three major labels: anti-tumor product + the only injection product + self paid drug According to IMS data, the market share of albumin taxol in China was 430 million yuan in 2018, and 2.03 billion yuan in 2019, a year-on-year increase of 372% All flow standards of sodium bicarbonate oral regular release dosage form In addition, 26 foreign enterprises participated in the centralized purchase, among which Riber, the original research enterprise, involved the most products, with 3 varieties and 4 specifications, mainly including acarbose, magnesium aluminocarbonate and moxifloxacin; GlaxoSmithKline, Pfizer, Servier, etc., all of which had 2 varieties This volume purchase involves three varieties not covered by the medical insurance (alisentan, tadalafil, albumin paclitaxel) According to the supplementary rules, non-medical insurance varieties enjoy the same prepayment and other policies, but it has nothing to do with medical insurance reimbursement Previously, it was predicted that 33 varieties will be purchased in the second batch According to the group's calculation, Qilu pharmaceutical, Kelun pharmaceutical, Yangzijiang pharmaceutical, Shiyao group and Hengrui pharmaceutical are expected to be big winners Qilu Pharmaceutical Co., Ltd has the largest number of products, up to 7 Six products from Kelun and Yangzi River are expected to participate in the bidding, while five from Shiyao group and four from Hengrui Pharmaceutical (including Chengdu Shengdi pharmaceutical) Among them, Qilu pharmaceutical mainly includes adefovir dipivoxil tablets, trimetazidine hydrochloride sustained-release tablets, sulindanin Succinate Tablets, tegio capsules, levocetirizine hydrochloride tablets, tadalafil tablets and albumin paclitaxel The second batch of national drug collection was officially launched on December 29 last year, involving 33 varieties and 50 specifications, covering the treatment fields of diabetes, hypertension, anti-tumor and rare diseases, and 122 pharmaceutical enterprises participated in the competition The total purchase amount is over 8.7 billion yuan, and the purchase amount of 15 kinds of drugs is over billion yuan, among which acarbose is the highest, reaching 2.9 billion yuan According to the data of minenet, by 2018, the total market size of domestic acarbose has reached 10 billion The purchasing base of this time is 12.4 billion pieces (bags / piece), and the agreed purchasing volume of each variety is 50-80% of the purchasing base For all shortlisted enterprises with less than 2 applications, up to 6 can be selected (when the application reaches 9 or more) Purchase quantity and purchase time: one enterprise is actually selected, 50% of the agreed purchase quantity calculation base in the first year, and the purchase cycle is one year; two enterprises are actually selected, 60% of the agreed purchase quantity calculation base in the first year, and the purchase cycle is two years; three enterprises are actually selected, 70% of the agreed purchase quantity calculation base in the first year, and the purchase cycle is two years; four or more enterprises are selected, the agreed purchase quantity calculation base in the first year 80% of the total, procurement cycle is 3 years According to the requirements of the documents, the shortlisted enterprises whose price meets one of the following conditions will be eligible for the shortlisted Enterprises: Unit comparable price ≤ 1.8 times of the lowest unit comparable price of the same variety Reduction of unit application price ≥ 50% Unit comparable price ≤ 0.1000 yuan As for the confirmation criteria of the supply area, it is also different from the previous one - the first ranking enterprises prefer to choose one area in the supply area After the completion of the priority selection, all the enterprises to be selected shall confirm the remaining areas alternately from the first ranking enterprise Each enterprise to be selected shall select one area at a time and repeat the above process until the completion of the selection and confirmation of all regions In addition, the enterprises to be selected shall confirm the supply area in combination with the capacity of their own enterprises When it comes to the selection, they must make confirmation and shall not abstain Otherwise, they shall be deemed to give up the qualification of the proposed selection, and other enterprises to be selected shall reconfirm the supply area according to the order It is worth noting that the national centralized drug purchase document also stipulates that when patients use the selected drugs, if personal injury is caused due to the production quality of the selected drugs, the selected enterprises shall bear the full liability for compensation in accordance with the drug administration law and other laws and regulations Whether the final decline of the second round of national drug centralized purchase will set a new record, and how to deal with the next round of national centralized purchase is worth thinking and attention Attachment: results of the second round of national drug pre selection